Search results
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with...
FOX 4 Kansas City· 9 hours agoJohnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort...
Johnson & Johnson wants to pay $6.5B to settle talcum-powder lawsuits over cancer claims
UPI· 4 days agoJohnson & Johnson's $6.5 billion settlement proposal -- to be paid over a 25-year period -- is the...
Robots Redefine Surgical Landscape for Enhanced Patient Outcomes
PYMNTS.com· 2 weeks agoRecent earnings reports from Intuitive Surgical and Johnson & Johnson highlight the surging demand...
FDA Approval of Alvotech/Teva Ustekinumab Biosimilar | JD Supra
JD Supra· 2 weeks agoOn April 16, Alvotech and Teva announced the FDA approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Johnson and
Alvotech and Teva’s Selarsdi™ (ustekinumab-aekn), Biosimilar to Stelara® Approved by FDA | JD Supra
JD Supra· 2 weeks agoAccording to an April 2024 press release, Alvotech and Teva’s Selarsdi™ (ustekinumab-aekn) was approved by the FDA on April 16 as a biosimilar of Janssen ...
New E. Coli Outbreak; How ECMO Redefines Death; A Step Closer to Universal Blood
MedPage Today· 5 days agoHealth news and commentary gathered by MedPage Today staff
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk...
FOX 5 San Diego· 2 days agoJohnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of ...
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical...
FOX 5 San Diego· 2 days agoJohnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) ...
2 Top Growth Stocks to Buy Right Now and Hold Forever
Motley Fool via Yahoo Finance· 1 week agoFood and Drug Administration (FDA) just approved Vertex's rolling new drug application submission...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 3 days agoThe technology is behind some of the biggest medicines on the market, including Johnson & Johnson's...